State Street’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

State Street’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-1,525,448	Closed	-$13.8M	–	3668
2013 Q4	$13.8M	Buy	1,525,448 +563,395	+59%	+$4.07M	﹤0.01%	2008
2013 Q3	$6.07M	Buy	962,053 +5,367	+0.6%	+$34.1K	﹤0.01%	2415
2013 Q2	$6.53M	Buy	+956,686	New	+$6.66M	﹤0.01%	2305

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street's CADX Position: Q1 2014 in Review

State Street sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 1,525,448 shares — an estimated $13.8M sold.

State Street first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $13.8M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

State Street reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
State Street sold 1,525,448 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $13.8M.
State Street first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
State Street's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $13.8M in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on State Street's 13F filing for Q1 2014, filed 13 May 2014.